<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03481400</url>
  </required_header>
  <id_info>
    <org_study_id>H-16014580</org_study_id>
    <nct_id>NCT03481400</nct_id>
  </id_info>
  <brief_title>CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment</brief_title>
  <official_title>Provoked Migraine Attacks With Calcitonin Gene-related Peptide (CGRP) in Patients Who Have Tried Preventive Treatment With Anti-CGRP Monoclonal Antibodies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the incidence of migraine attacks after calcitonin
      gene-related peptide (CGRP) infusion in patients who have tried anti-CGRP monoclonal antibody
      treatment for the prevention of migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcitonin gene-related peptide (CGRP) plays a role in migraine pathophysiology. Infusions of
      CGRP can trigger migraine-like attacks in migraine patients and antibodies against CGRP or
      the CGRP receptor significantly reduces the number of migraine days per month when
      administered regularly. Some patients however, do not experience migraine attack after CGRP
      infusion, and some do not experience migraine reduction with antibodies. The underlying
      mechanisms of these effects are largely unknown.

      The purpose of this study is to examine CGRP-induced migraine in patients who have evaluated
      the efficacy of anti-CGRP monoclonal antibody treatment for migraine using a
      purpose-developed standardized interview. The investigators will use a double-blind,
      placebo-controlled crossover study design to examine migraine susceptibility to CGRP in these
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Placebo-controlled, crossover design.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of migraine</measure>
    <time_frame>From 0 to 12 hours after CGRP infusion</time_frame>
    <description>Incidence of migraine after CGRP infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve of headache intensity</measure>
    <time_frame>From 0 to 90 minutes after infusion and from 90 minutes to 12 hours after infusion</time_frame>
    <description>Area under the curve of headache intensity from 0-90 min and 90 min-12 hours post infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>From 0 to 90 minutes after infusion</time_frame>
    <description>Heart rate (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>From 0 to 90 minutes after infusion</time_frame>
    <description>Blood pressure (millimeter of mercury)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Calcitonin gene-related peptide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcitonin gene-related peptide infusion (1.5 micrograms/min for 20 mins)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion with placebo (isotonic saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitonin Gene-Related Peptide</intervention_name>
    <description>Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)</description>
    <arm_group_label>Calcitonin gene-related peptide</arm_group_label>
    <other_name>CGRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Isotonic saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of migraine according to the international classification of headache
             disorders version 3-beta

          -  Subject has tried anti-CGRP antibodies for migraine

          -  Women of childbearing potential are on safe contraception

        Exclusion Criteria:

          -  Women of childbearing potential who do not use contraception. Includes
             non-hysterectomized women who have not been menopausal for at least two years. Safe
             contraception includes condoms, intrauterine devices, p-pills, surgical sterilization
             or gestagen injections.

          -  Daily drug intake apart from contraceptives and preventive medication for migraine.

          -  Ingestion of any drug 4 half-lifes before study start apart from contraceptives.

          -  Pregnant or breast-feeding women

          -  Migraine on the study day or less than 48 hours before CGRP infusion.

          -  A history of cardiovascular and/or cerebrovascular disease

          -  Systolic blood pressure &gt;150 mmHg and/or diastolic blood pressure &gt; 100 mmHg on study
             day.

          -  Systolic blood pressure &lt;90 mmHg and/or diastolic blood pressure &lt; 50 mmHg on study
             day.

          -  A history of mental illness

          -  A history of any illness or condition that is deemed relevant for participation by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Messoud Ashina, prof.</last_name>
    <role>Study Director</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Casper E Christensen, MD</last_name>
    <phone>38632027</phone>
    <email>casper.emil.christensen.03@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samaira Younis, MD</last_name>
    <phone>38632176</phone>
    <email>samaira.younis.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danish Headache Center, Rigshospitalet Glostrup</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casper E Christensen, MD</last_name>
      <phone>38632027</phone>
      <email>casper.emil.christensen.03@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Samaira Younis, MD</last_name>
      <phone>38633863</phone>
      <email>samaira.younis.01@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Casper Emil Christensen</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>Calcitonin gene-related peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

